Opinion|Videos|January 27, 2025
Exploring the Pediatric Patient and Caregiver Journey
Panelists discuss the patient journey for patients with pediatric atopic dermatitis (AD) and their caregivers, from initial presentation through to diagnosis, emphasizing the challenges and emotional aspects that families experience throughout the process.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Describe the patient journey for pediatric patients with AD and their caregivers from initial presentation to diagnosis.
Advertisement
Related to this article
Researchers found that childhood unpredictability provided additional information about mental health risk beyond conventional ACEs screening.
Lavengratinib increased annualized height velocity in 7 children with achondroplasia, but open-label phase 2 findings remain preliminary.
The FDA granted satralizumab priority review for MOGAD after phase 3 findings showed a 68% reduction in relapse risk versus placebo.
Suicide-related pediatric ED visits rose 74% from 2016 to 2022; about half occurred at EDs with lower pediatric volume, a national analysis found.
Amélie Lothe, PhD, discusses findings showing early, sustained benefits of fenfluramine treatment for patients with Lennox-Gastaut syndrome.
FDA approved levacetylleucine (Aqneursa) for ataxia in ataxia-telangiectasia, the first therapy for the disease, in patients 15 kg or heavier.
Tallie Z. Baram, MD, talks about how adding a measure of childhood unpredictability to ACEs screening may help pediatricians identify children at risk for mental health problems.
Review some of the top stories from the Contemporary Pediatrics website over the last week, and catch up on anything you may have missed.
Advertisement
Advertisement
Trending on Contemporary Pediatrics
1
Suicide-related emergency department visits in US children rose 74% from 2016 to 2022
2
Fenfluramine shows sustained seizure reduction, functional improvement in Lennox-Gastaut syndrome
3
Formula Feeding and the Gut Microbiome: Closing the Gap
4
Satralizumab for MOGAD gains FDA priority review after phase 3 relapse reduction
5